484 related articles for article (PubMed ID: 12750839)
1. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
[TBL] [Abstract][Full Text] [Related]
2. Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small cell lung cancer (JCOG 9807).
Yamada K; Ikehara M; Tanaka G; Nomura I; Oshita F; Noda K
Oncology; 2004; 66(2):94-100. PubMed ID: 15138360
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of vinorelbine and irinotecan in previously untreated patients with advanced non-small cell lung cancer.
Tomonaga N; Nakamura Y; Soda H; Nagashima S; Nakano H; Kinoshita A; Fukuda M; Fukuda M; Takatani H; Soejima Y; Oka M; Kohno S;
Cancer Chemother Pharmacol; 2008 Jun; 62(1):43-9. PubMed ID: 17717667
[TBL] [Abstract][Full Text] [Related]
4. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
[TBL] [Abstract][Full Text] [Related]
5. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer.
Fujita A; Takabatake H; Tagaki S; Sekine K
Cancer Chemother Pharmacol; 2000; 45(4):279-83. PubMed ID: 10755315
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer.
Nogami N; Harita S; Ueoka H; Yonei T; Kiura K; Kamei H; Tabata M; Segawa Y; Gemba K; Tanimoto M
Lung Cancer; 2004 Jul; 45(1):85-91. PubMed ID: 15196738
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer.
Goya H; Kuraishi H; Koyama S; Ichiyama T; Yoshiike F; Hirai K; Agatsuma T; Tateishi K; Kanda S; Yamamoto H; Kubo K; Koizumi T
Cancer Chemother Pharmacol; 2012 Nov; 70(5):691-7. PubMed ID: 22941346
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
11. A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.
Hotta K; Ueoka H; Kiura K; Tabata M; Kuyama S; Satoh K; Kozuki T; Hisamoto A; Hosokawa S; Fujiwara K; Tanimoto M
Lung Cancer; 2004 Jul; 45(1):77-84. PubMed ID: 15196737
[TBL] [Abstract][Full Text] [Related]
12. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
Frasci G; Comella P; Thomas R; Di Bonito M; Lapenta L; Capasso I; Botti G; Vallone P; De Rosa V; D'Aiuto G; Comella G
Cancer Chemother Pharmacol; 2004 Jan; 53(1):25-32. PubMed ID: 14513281
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer.
Oshita F; Yamada K; Saito H; Noda K
Cancer Chemother Pharmacol; 2008 Aug; 62(3):465-70. PubMed ID: 17960380
[TBL] [Abstract][Full Text] [Related]
15. Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
Kiura K; Takigawa N; Segawa Y; Tabata M; Shibayama T; Gemba K; Bessho A; Fujimoto N; Takata I; Hotta K; Fujiwara K; Tokuda Y; Kuyama S; Shinkai T; Ueoka H; Tanimoto M;
J Thorac Oncol; 2007 Jan; 2(1):44-50. PubMed ID: 17410009
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer.
Okuda K; Hirose T; Ishida H; Kusumoto S; Sugiyama T; Ando K; Shirai T; Ohnishi T; Horichi N; Ohmori T; Adachi M
Cancer Chemother Pharmacol; 2008 Apr; 61(5):829-35. PubMed ID: 17589845
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.
Yoda S; Soejima K; Yasuda H; Naoki K; Kawada I; Watanabe H; Nakachi I; Satomi R; Nakayama S; Ikemura S; Terai H; Sato T; Morosawa M; Asano K
Cancer Chemother Pharmacol; 2011 Mar; 67(3):717-22. PubMed ID: 21152917
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.
Socinski MA; Sandler AB; Miller LL; Locker PK; Hanover CK; Elfring GL; Israel VK; Pirotta N; Natale RB
J Clin Oncol; 2001 Feb; 19(4):1078-87. PubMed ID: 11181672
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of amrubicin and nedaplatin in patients with untreated, advanced, non-small cell lung cancer.
Ogawara D; Nakamura Y; Fukuda M; Nakatomi K; Yamaguchi H; Motoshima K; Mizoguchi K; Nakano H; Takemoto S; Gyotoku H; Nagashima S; Kohno S
Chemotherapy; 2014; 60(3):180-4. PubMed ID: 25823897
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.
Chang MH; Kim KH; Jun HJ; Kim HS; Yi SY; Uhm JE; Park MJ; Lim DH; Ji SH; Hwang IG; Lee J; Park YH; Ahn JS; Ahn MJ; Park K
Cancer Chemother Pharmacol; 2009 Oct; 64(5):917-24. PubMed ID: 19221753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
